INTRODUCTION

Epstein-Barr virus (EBV) invades Blymphocytes through molecular interactions involving the EBV gp350/220 protein. It is known that gp350 binds to B-lymphocyte CR2
(known as C3d-receptor) with a 3.2 nM affinity constant (12 nM affinity has been determined for B-lymphocyte surface) (1-2); this simple 1:1 interaction is involved in adsorption, capping and EBV-endocytosis and is considered to be a primary determinant of EBV-tissue tropism (3) (4) (5) . The CR2-region binding to gp350 overlaps CR2-region binding to C3dg. The gp350 Nterminal region contains part of the Blymphocyte binding domain (5) .
The gp350 21 EDPGFFNVE 29 peptide, having significant homology with C3d-amino acid sequences (6) , binds to purified CR2 and to CR2(+) but not to CR2(-) B-and Tlymphoblastoid cell lines; this peptide coupled to BSA inhibits CR2-binding to EBV and gp350 (7) . This peptide inhibits C3dg-binding to Bcells (as well as EBV) and also inhibits C3-induced Raji cell proliferative response (7) (8) .
However, the 470-mer N-terminal recombinant protein and gp220, containing this peptide sequence, present single-component binding whilst gp350/220 presents a higher affinity two-component binding to CR2 (5, 9) and only inhibits 50% of EBV-binding and EBVinfection of Raji cells (5 ) does not inhibit peptide 16 
IHLTGEDPGFFNVE
29 Raji binding or block virus adsorption or infectivity (5) . On the other hand, the C3dg region (homologous to this gp350 peptide), is not in contact with CR2 in the reported complex structure (10) . It is thus very likely that other gp350/220 regions are involved in EBV-binding to B-lymphocytes.
The gp350/220 region containing the epitope recognised by neutralising monoclonal antibody 72A1 is one of the most important regions involved in gp350/220-binding to Blymphocyte CR2, since the mAb-72A1 Fabfragment inhibits EBV-binding and invasion of host cells (5, 11) ; moreover, mAb-72A1 inhibits EBV-invasion of monocytes (12), neutrophils (13) and T-cells (14) . Anti gp350/220 mAb-72A1, also inhibits IL-6 protein synthesis induced in PBL by gp350/220 binding to CR2 (15) , therefore EBV-invasion of B-lymphocytes also (5) . It is known that the gp350/220-region involved in EBV-invasion of host cells is recognised by this monoclonal antibody; however its precise localisation remains unknown. The purpose of this work was thus to identify B-lymphocyte binding sequences involved in EBV-virus infection of Blymphocytes, probably recognised by mAb-72A1.
Materials and Methods
Peptide synthesis. Forty-six peptides, covering the total length of EBV-gp350 reported sequence (16) , were synthesized by the solid phase method (17) with N-terminal t-Boc-protected amino acids. Peptides were cleaved by Low-High HF protocol (18) . These peptides were analyzed by mass spectrometry and RP-HPLC. Synthesized peptide sequences are shown in Figure 1 . Tyrosine (Y) was carboxyl terminal added, allowing those peptides not containing this amino acid to be radio-labeled. Lymphoblastoid cell-line cultures. The cloned Raji (19) , Ramos (20) and P3HR-1 (21) lymphoblastoid cell lines and HeLa cells (22) were kept in culture in adjusted RPMI 1640 (Gibco BRL) supplemented with 10% fetal bovine serum (FBS, Hyclone), containing 2mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES (Gibco BRL) and 1 mM sodium pyruvate. All the cells were grown at 37°C in a 5% humidified CO 2 atmosphere. HeLa cells, cultured in monolayers, were harvested by adding PBS-EDTA, followed by spinning at 1,000 × g for 5 min. Cells were washed three times for 5 min at 1,000 x g with (10 4 cells µl -1 ) in the absence (total binding) or presence (non-specific binding) of unlabeled peptide (1.25 µM) for 1 h at 18°C. Cells were then separated from the medium by spinning at 10,000 x g for 1 min through a dibutylphthalatedioctylphthalate cushion (d=1.015 g ml -1 ). Cellbound 125 I-labeled peptide was measured; specific binding for each peptide was calculated as being the difference between total and nonspecific binding. Cell binding activity for each peptide was defined as being the ratio of specific binding over the amount of added radio-labeled peptide. Nemerow's peptide (peptide 11420), which specifically binds to Raji cell (7) (used as positive binding control peptide), presented 0.034 binding activity. High activity binding peptide saturation curves were constructed with 10 4 cells µl -1 , 125 I-labeled peptide at 5-700 nM concentration in the absence or presence of 40 µM unlabeled peptide. Hill analysis was performed as previously reported (24) . Briefly, bound (b) and non-bound (Free) peptide was measured in saturation assays; Hill plots were built using Y-axis as Log (b/(bmax-b) and Xaxis as Log (Free); bmax represents the maximum number of cell receptors to which the peptide could bind to (depend of the total number of peptide cell receptors). ELISA. Plates were coated with 1µg peptide per well in 100µl PBS at 4°C overnight; they were subsequently blocked with a 2% of fat-free dry milk in PBS 0.2% Tween 20 (PBSMT) for two hours at 37°C. 100  µl of the appropriate serial rabbit sera dilutions were added and incubated for two hour at 37°C. The wells were then incubated with a 1/5,000 dilution of anti-rabbit peroxidase (VECTOR) at 37°C for one hour, followed by colour-development with a solution prepared by TMB peroxidase substrate (KPL) for 15 min; absorbancy was read at 620 nm. For sandwich ELISA plates were coated with 100 µl mAb 72A1 (2.5 µg/ml) in PBS at 4°C overnight. Plates were then blocked with PBSMT for one hour at 37°C. Wells were subsequently incubated with increasing peptide solutions (0.3125 to 10 µg/ml) or with different EBV-dilutions (1/10 to 1/320) for two hours at 18°C. Wells were then incubated with 100 µl 1/4000 anti-EBV or anti-HABP rabbit serum dilutions for two hours at room temperature. Control wells were treated in a similar way but using PBS instead of mAb-72A1. The conditions for the competitive sandwich ELISA were (established by using HABP-or EBV-mAb-72A1 binding curves): 4 µg/ml 11382, 0.15 µg/ml 11389 or 4 µg/ml 11416 HABPs bound to mAb-72A1 in the presence of 1/20 to 1/1280 EBV-dilutions; 1/20 EBV-dilution were bound to mAb 72A1 in the presence of 0.0024 to 10 µg/ml HABPs, for two hours at room temperature. Plates were then incubated with 100 µl anti-HABP (1/4,000 dilution) or anti-EBV (1/500 dilution) sera for two hours at 18°C. Colour-development was performed as mentioned above (26) . Flow cytometry analysis. 500,000 cells were washed twice with 0.5% PBS-BSA, spinning at 2,500 rpm for 5 min, for flow cytometry analysis. The cells were then treated with a flow cytometry fixation and permeabilisation kit (DAKO), according to Manufacturer's instructions. The cellular pellet was suspended in 100 µl 0.5% BSA-PBS, containing a 1/640 serum dilution or with 100 µl 1/400 72A-1 monoclonal antibody dilution on ice for 45 min. This mixture was incubated for 50 min at 18°C. The cells were then washed three times with BSA-PBS, spinning at 2,500 rpm, for 5 min; incubated with 100 µl 1/200 dilution of FITClabeled goat anti-rabbit IgG F(ab)2 and phycoerythrin labeled rat anti human-TCR for 30 min at 4°C or with 100 µl 1/50 dilution FITClabeled anti-mouse IgG F(ab) 2 (VECTOR) and finally washed twice with PBS. Fluorescence cells were read by Becton Dickinson FACScan. Rabbit antibody isolation. Rabbit sera were diluted four times with 60 mM acetate buffer, pH 4.0; the pH was then raised to 4.5 by adding 0.1 N NaOH. 25 µl/ml caprylic acid were added and stirred for 30 min. Samples were then centrifuged at 10,000×g for 30 min and the supernatant was separated. 1/10 volume of 10×PBS was added to the obtained supernatant and the pH adjusted to 7.4 with 0.1 N NaOH. The immunoglobulin fraction was precipitated with 0.35 g/ml ammonium sulfate overnight at 4°C. The pellet was separated by spinning at 5,000×g for 15 min at 4°C and suspended in PBS. The immunoglobulin solution was extensively dialyzed with PBS. Isolated protein concentration was determined by Bradford test (100-170 µg/ml) and antibody activity by ELISA and immunofluorescence (27) .
Epstein-Barr virus invasion of CBLs. 2×10
5 cord blood lymphocytes (in 100 µl RPMI-1640 supplemented with 10% heat-inactivated serum, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.4 µg/ml cyclosporine A and 5 mM CaCl 2 ) were incubated with 30 µl EBV-containing supernatant for 30 min at 37°C in 5% CO 2 atmosphere. 70 µl RPMI-1640 medium were then added and the samples incubated for 16 h at 37°C in 5% CO 2 atmosphere. After incubation, cells were washed three times with RPMI-1640 medium (FBS free) and their DNA was obtained for PCR-amplification. CBLs were pre-incubated with 8 µM HABPs for 15 min at 37°C or 30 µl EBV were pre-incubated with 30 µl rabbit isolated antibodies (100-170 µg/ml), for one hour at 37°C before EBV-invasion assays were performed for determining the effect of HABP or anti-HABP antibodies on EBV-invasion of CBLs. EBV-invasion of CBLs without HABPs or isolated antibodies was used as positive control. CBLs, treated in the same conditions as a positive control but without EBV-supernatant, were used as a negative control.
EBV-DNA identification by PCR-amplification.
DNA was obtained by proteinase K digestion, phenol-chloroform extraction and ethanol precipitation. This DNA was dissolved in 20µl TE buffer (10 mM TRIS-HCl, pH 8.0; 1mM EDTA), 0.5 mg/ml final concentration (28) . PCR was performed in 20 µl reaction mixture containing 10 mM TRIS-HCl (pH 8. 6 PBLs were incubated with 150 µl EBV or 13.3 µM of each HABP for 96 h at 37°C. The supernatant thus obtained was stored at -20°C until IL-6 protein was determined by ELISA, according to Manufacturer's instructions. The effect of 10 µg/ml mAb 72A1 on IL-6 protein synthesis induced by HABP-11382, -11389 (11 µM) or EBV was determined. In other experiments, EBV was treated for 15 min at 4°C with 100-160 µg/ml anti-HABP or anti-EBV isolated antibodies, or with 10 µg/ml mAb 72A1 to determine these antibodies' effect on EBVinduced IL-6 protein synthesis. Also, the effect of 10 µg/ml mAb 72A on EBV-induced IL-6 protein synthesis was determined in the presence of 8 µM HABP-11382, -11389 or -11416.
RESULTS
Identifying B-lymphocyte binding regions in gp350.
gp350/220 specifically binds to the CR2-molecule, which has been found on Raji and Ramos but not on P3HR-1 cells (31) (32) . Raji and Ramos cells were thus chosen as positive cell binding control and P3HR-1 as negative cell binding control for selecting B-lymphocyte binding gp350-peptides. The CR2-molecule was determined on Raji and Ramos cells, but not on P3HR-1, by using flow cytometry analysis with the previously reported CR2-recognizing monoclonal antibody (33) (data not shown).
Peptides 11381, 11382, 11388, 11389 and 11394 from the gp350 N-terminal region, and 11415 and 11416 from the gp350 C-terminal region, presented CR2(+) Raji and Ramos cell binding activity higher than or equal to 0.034 (the known value for the binding activity of Nemerow's peptide) but not to CR2(-) P3HR-1 cells (Fig. 1) (Table 1) .
CR2(+) cell HABPs inhibited EBV-attachment to B-lymphocytes
gp350/220 binding to CR2 on PBLs induces interleukin-6 (IL-6) synthesis (15, (34) (35) ; PBLs were thus exposed to CR2(+) cell HABPs and IL-6 protein synthesis level was determined in these cell cultures' supernatant. PBLs exposed to HABPs 11381, 11388, 11389, 11394 or 11415 showed IL-6 protein levels similar to that of non-treated PBLs, suggesting that these peptides did not have any affect on IL-6 synthesis. On the contrary, PBLs exposed to HABPs 11382 and 11416 increased four times IL-6 protein levels, similar to IL-6 protein levels induced in PBLs by exposure to EBV (Fig. 2,A) .
It is probable that mAb-72A1 binds to some of these HABP-sequences. ELISA revealed that HABPs 11382, 11389 or 11416 specifically bound to mAb-72A1 in a dose-dependent way, showing 72%, 100% or 55% EBV-binding to mAb-72A1 (respectively), having antibody titres higher than or equal to 25,600, at 10 µg/ml peptide. On the other hand, HABPs 11381, 11388, 11394 or 11415 presented no significant binding to mAb-72A1 at the same peptide concentrations (lower than 20% of the binding obtained with EBV) (Fig. 2,B) . Moreover, HABPs 11382, 11389 or 11416, but not the nonrelevant peptide, inhibited mAb-72A1 binding to EBV in a dose dependent manner, just as EBV did, as determined by ELISA (Fig. 2C ). PBLs were also exposed to HABPs 11382, 11389, 11416 or EBV in the presence or absence of mAb-72A1 and IL-6 protein levels were then determined; mAb-72A1 inhibited more than 50% of IL-6 protein synthesis induced by HABPs 11382, 11416 or EBV (Fig. 2D) . Furthermore, the effect of mAb-72A1 on EBV-induced IL-6 synthesis was eliminated when mAb-72A1 had been previously incubated with HABPs 11382, 11389 or 11416 (Fig. 2E) .
CR2(+) cell HABPs induced antibodies recognizing EBV-infected cells and inhibited IL-6 protein synthesis induced by EBV-binding to PBLs.
Each rabbit was immunized with one of the CR2(+) cell HABPs; these peptides induced antibodies with anti-HABP antibody titers between 6,400 and 51,200, as determined by ELISA. These anti-HABP antibodies also recognized EBV by ELISA, but with lower antibody titres (between 3,200 and 25,600) (Fig.  3A) . On the other hand, anti-EBV antibodies were able to recognize these HABPs with antibody titres between 1,600 and 6,400.
Anti-HABP antibodies, isolated from rabbit sera through precipitation with caprylic acid and ammonium sulfate, specifically recognized a 11.3 ± 3.2% mean of TPAstimulated B95-8 cells (EBV-infected cells) but only 1.6 ± 0.5% of CBLs (non-EBV-infected cells) by flow cytometry. Anti-EBV antibodies recognized around 31.64% of B95-8 cells and only 3.86% of CBLs. On the contrary, antibodies isolated from sera obtained before the first immunization or anti-non-relevant peptide antibodies only recognized a 2.6 ± 1.8 mean of the B95-8 cells or CBLs (Fig. 3B) . EBV-binding to PBLs induced IL-6 protein synthesis in these cells; but when EBV was previously treated with anti-HABP 11382, 11389 or 11416 antibodies, the IL-6 protein synthesis induction diminished between 50 and 70%, in the same way that anti-EBV antibodies did. This effect was not seen with anti non-relevant peptide antibodies (Fig.  4) .
CR2(+) cell HABPs 11382, 11389 and 11416, or their anti-HABP antibodies, inhibited EBVinvasion of CBLs.
EBV was able to invade CBLs, not only because virus presence in these cells could be determined by PCR-amplification of the highly specific 300 bp DNA fragment, but also because anti-gp250/350 mAb-8174 (Chemicon) recognized 31.6% of EBV-treated CBLs whilst only recognizing 2% of EBV-non treated CBLs by flow cytometry analysis (data not shown).
EBV-invasion of CBLs was performed in the presence of each CR2(+) cell-HABP or anti-HABP antibody. HABPs 11381, 11388, 11394 and 11415, or their anti-HABP antibodies, did not have a significant effect on EBVinvasion of CBLs, since EBV-DNA was detected by PCR in these cells (Fig. 5) . On the contrary, EBV-invasion of CBLs in the presence of HABPs 11382, 11389 and 11416, or their anti-HABP antibodies, was significantly inhibited, since EBV-DNA was not detected in these cells (Fig. 5) .
DISCUSSION
The aim of this work was to find gp350/220 regions involved in EBV-binding to CR2(+) cells by using synthetic peptides; this approach has previously been used for defining protein regions involved in virus and host cell interactions (36) (37) (38) (39) (40) (41) (42) (43) . The initial screening binding assay was performed using Raji cells because they express CR2, bind EBV and support virus-cell fusion (44); Nemerow's peptide was used as positive control, since it specifically binds to these cells (7) . Binding assays were performed at low peptide concentrations (2-12 nM) for identifying high affinity and high capacity binding peptides.
Raji binding peptides 11378, 11410, 11411 and 11412, which also bound to CR2(-) P3HR-1 cells, and 11401 to 11405 and 11423, which did not bind to CR2(+) Ramos cells, were discarded from further study as gp350 specifically binds to CR2(+) cells but not to CR2(-) cells. However, peptides 11401 to 11405, from the repeat region (residues 502 to 621), could be involved in EBV-invasion of Blymphocytes, since the 576-mer N-terminal fragment binds to Raji cells, inhibits EBV binding to lymphocytes and blocks EBVinfection more efficiently than the 470-mer Nterminal fragment (lacking the 471-576 region) (5). Furthermore, the VTTPTPNATSPTLGKT sequence is the target for anti-EBV neutralising monoclonal antibodies (45) . HABPs 11402, 11403 and 11404 contain this reported epitope (underlined as follows SAVTTPTPNATSPTLGKTSPT); HABPs 11401 and 11405 contain only part of this (AVTTPTPNATSPT). The differences in cell binding tropism between B95-8 EBV (containing the repeat region) and P3HR-1 EBV (which does not contain this region) could be due to this binding region (46) (47) .
HABPs 11381, 11382, 11388, 11389, 11394, 11415 and 11416 specifically bound to CR2(+) cells (Raji and Ramos) but not to CR2(-) cells (P3HR-1) and, taking into account that gp350/220 specifically binds to CR2 molecules, these HABPs were therefore considered to be putative CR2-binding sequences. CR2(+) HABPs 11381, 11382, 11388, 11389 and 11394 were located in the gp350/220 576-mer Nterminus fragment, containing part of the Rajibinding region, since this fragment bound to Raji cells in a similar way to the entire gp350/gp220 (5, 48) . HABPs 11415 and 11416 were located in the C-terminal region, specifically in the immuno-dominant region recognised by anti-EBV human neutralising antibodies (49) (50) .
The CR2(+) HABPs showed saturable binding, having a finite number of HABPbinding sites per Raji cell, supporting the idea of specific binding receptors. The affinity constants were in the 40-340 nM range (Table 1) , showing strong interaction between these HABPs and Raji cells which could be very important for efficient EBV-binding to B-lymphocytes (except for HABP-11381 for which the affinity constant could not be obtained). HABPs 11382, 11388, 11389, 11394 and 11416 presented a single type of interaction. On the contrary, HABP-11415 presented a 2.0 Hill coefficient, suggesting positive cooperativity, and could be seen as a parallel increase in affinity accompanied by increased HABP-binding to Raji cells. This peptide perhaps bound with different affinity to at least two different receptors that could also interact with each other i.e. CD21 and MHC class II which are known to bind peptides having this length (51) (52) .
It is known that gp350/220 binding to CR2 increases IL-6 protein synthesis on PBLs; mAb-72A1 inhibits gp350/220-binding and therefore inhibits EBV-induced IL-6 protein synthesis. In our work, HABPs 11382, 11389 and 11416 bound to mAb-72A1, inhibited mAb-72A1 binding to EBV and blocked the effect of mAb-72A1 in inhibiting EBV-induced IL-6 protein synthesis. HABPs 11382, 1389 and 11416 bound to mAb-72A1, in spite of there being no apparent homology amongst them. This agrees with other reports which have revealed that highly specific antibodies frequently show cross-reactivity, even in unrelated epitopes (53) (54) . It was also found that HABPs 11382 and 11416 induced IL6-synthesis in PBLs in the same way that EBV did and this induction was inhibited by mAb-72A1.
CBLs exposed to EBV in the presence of non-relevant peptide were invaded by EBV since EBV-DNA was detected in these cells (Fig. 6) . On the contrary, CBLs exposed to EBV in the presence of CR2(+)-cell HABPs 11382, 11389 and 11416, were not significantly invaded by this virus, since EBV-DNA was not detected by PCR-amplification in these cells (Fig. 6 ).
All these data indicate that HABPs 11382, 11389 and 11416 specifically inhibited EBV-invasion of B-lymphocytes, probably by blocking EBV-binding to host cells. HABPs 11382, 11389 and 11416 not only contain gp350 regions involved in EBV-binding to host cells but also regions recognised by mAb-72A1, supporting the previously reported hypothesis that mAb-72A1 probably binds to the WCHHAEMQNPVYLIPETVPYIKW sequence (HABP 11382 is underlined) according to the results obtained with gp350/220 recombinant fragments (5) .
Interestingly, LALING and GETAREA software (55; http://www.scsb.utmb.edu/getarea/area_form.htl m) have revealed that these HABPs have homology with the C3d-regions coming into contact with CR2 in the resolved co-crystal structure (C3d-residues coming into contact with CR2 are shown in bold; identical or similar amino acids are shown in larger capital letters) (10).
HHAEMQNPVYLIPETVPYIK
C3d LILEKQKPDGVFQEDAPVIH 11389 YVFYSGNGPKASGGDYCIQS C3d EQVNSLPGSITKAGDFLEAN 11416 PSTSSKLRPRWTFTSPPVTTY C3d
PSSAFAAFVKRAPSTW LTAY
These three binding regions could be held together in the gp350-structure, assembling a single binding site, as seen in the C3dg-CR2 resolved co-crystal structure of the complex. In fact, a chimera was built by homology modelling based on the C3dg-CR2 complex structure (Protein data bank code 1GHQ), in which C3dg CR2-contact regions were changed (i.e. replacements were made in C3dg but not in CR2) by HABP-11382, 11389 and 11416 sequences, using Insight II (2000) Biopolymer module software (Accelrys Inc. Software, USA) run on an Indigo 2 Station (Silicon Graphics). The minimised chimerical and C3dg-CR2 resolved co-crystal structure of complex were superimposed, revealing that the structures were very similar; contact residues were conserved (including secondary structure elements) and 2.8 Å root mean square deviation (RMSD) values were presented for the overall structure and 1.25 Å for the contact regions in both proteins ( Figure  6 ). This was in part due to interaction between CR2 and C3dg being mainly mediated through backbone atom interaction (10) . This suggests that in addition to these HABP-sequences not disturbing the resolved co-crystal structure of the C3dg-CR2 complex contact regions, HABPsequences could also supply the C3dg-protein function for binding to CR2 in the chimerical complex.
Anti-gp350/220 antibodies, inhibiting EBV-binding to B-lymphocytes, are involved in protection against EBV-infection. In fact, gp350/220 induces anti-EBV neutralising antibodies, restricting viral pathogenesis in vivo and virus-infection in vitro (46, 56) . It has also been reported that gp350-immunised marmosets are protected from EBV-infection, developing gp350-reacting antibodies, several of them exhibiting virus neutralising activity (57) . Neutralising antibody epitopes on gp350/220 are generally not glycosylation-dependent (58); some of them are located on the amino acid backbone (59) , suggesting that the amino acid sequence of this protein induces protective antibodies. The gp350/220 B-lymphocyte binding regions are thus suitable targets for inducing protective immunity against EBVinfection.
Each rabbit immunised with one of the CR2(+) cell HABPs induced specific anti-HABP antibodies which also recognised EBV (Fig.  3,A) , with anti-HABP antibody titres higher than anti-EBV antibody titres, except for serum from rabbit 423 (Fig. 3,A) . These HABPs were recognised by anti-EBV antibodies but with lower anti-HABP titres than anti-EBV titres (Fig.  3A) . This suggests that there are differences between peptide-and protein-structure and/or differences in epitope accessibility in these sequences.
Anti-HABP antibodies specifically recognised around 10% of EBV-infected cells (B95-8 cells) by flow cytometry analysis (Fig.  3B) ; interestingly, a similar percentage of TPAtreated B95-8 cells enter the viral lytic cycle (60) . Anti-EBV antibodies recognised a high percentage of B95-8 cells, suggesting that some EBV-antigen inducing these antibodies was expressed in the majority of B95-8 cells, not only viral lytic cycle cells. These results showed that these HABPs are immunogenic and antigenic, that anti-HABP antibodies recognise some EBV-native antigen in EBV-infected cells (probably gp350) and that the whole HABPsequence (or part of it) is exposed on native protein in EBV-infected cells.
Anti-HABP 11382, 11389 or 11416 antibodies significantly inhibited the IL-6 protein synthesis induced by EBV and EBV-invasion of CBLs (Fig 5) , probably because these antibodies inhibited gp350-binding to CR2, taking into account that these HABPs contain gp350 regions involved in EBV-binding to host cells. These results suggest that HABPs 11382, 11389 and 11416 are capable of inducing antibodies inhibiting EBV-binding of host cells in which EBV-invasion is mediated by gp350/220. These results agree with other reports showing that monoclonal and human neutralising antibodies recognise epitopes between gp350 residues 65-174 and 236-327 in which HABPs 11382 and 11389 are (respectively) located (5, 45, 49, 50) .
HABPs 11382, 11389, and 11416 clearly bound with high affinity to EBVsusceptible cells, inhibited EBV-binding to Blymphocytes, were recognised by mAb-72A1, elicited antibodies not only interacting with EBV-infected cells but also inhibiting EBVbinding and invasion of B-lymphocytes. The above thus suggests that HABP-11382, 11389 and 11416 sequences are involved in EBVbinding and invasion of B-cell lymphocytes and could be used not only for designing strategies against EBV-induced diseases (i.e. EBV-induced post-transplant lymphoproliferative disorder), but also for designing prophylactic EBV-vaccine candidates.
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The abbreviations used are: EBV, Epstein Barr virus; HABP, high activity binding peptide; PBLs, peripheral blood lymphocytes; CBLs, cord blood lymphocytes; BSA, bovine serum albumin; PBS, PBS, phosphate buffered saline; IL-6, interleukin 6; PCR, polymerase chain reaction; mAb, monoclonal antibody. Fig. 1 . gp350/220 peptide Raji, Ramos and P3HR-1 cell binding activities. The column giving peptide numbers uses our lab's peptide accession codes. The protein position appears in the second column along with sequences for gp350/220 peptides used in this paper. The black bar column represents Raji, Ramos and P3HR-1 binding activity, calculated as stated in Materials and Methods. Fig. 2 . HABP-binding to PBLs and their effect on IL-6 protein synthesis. HABP 11382, 11389 and 11416 sequences probably contain the gp350/220 binding region that interacts with CR2 on PBLs. In A, PBLs were exposed to EBV (C(+)) or to CR2(+)-cell HABPs. IL-6 protein levels were determined by ELISA. It is shown that HABPs 11382 and 11416 induced IL-6 protein synthesis in the same way that EBV did (C(+)). In B, CR2(+) cell HABP binding to mAb-72A1 at different concentrations was determined by ELISA. It is shown that HABPs 11382, 11389 or 11416, but not 11381, 11388, 11394 or 11415, were specifically recognized by mAb-72A1. In C, mAb-72A1-binding to EBV was performed in the presence of HABPs 11382, 11389 and 11416, non-relevant peptide (25684) or EBV. It is clearly shown that HABPs 11382, 11389 or 11416 inhibited mAb-72A1-binding to EBV in a dose-dependent manner; on the contrary 25684 did not. In D, PBLs were exposed to HABPs 11382, 11389 or 11416 in the presence (white bars) or absence (grey bars) of mAb-72A1; this inhibited IL-6 protein synthesis induced by HABPs 11382 and 11416; a non-relevant mAb (mAb NR) did not inhibit IL-6 induced by EBV. In E, PBLs were exposed to EBV in the presence or absence of mAb-NR (which did not inhibit IL-6 induced by EBV) or mAb-72A1 (which inhibited IL-6 induced by EBV) plus HABPs 11382, 11389 or 11416; it is shown that HABPs 11382, 11389 and 11416 blocked the effect of mAb-72A1 on EBV-induced IL-6 protein synthesis in PBLs. Fig. 3 . Anti-HABP antibody reactivity against peptides and EBV-infected cells by ELISA and flow cytometry analysis. In A, anti-HABP or anti-EBV antibody serum titers from rabbits immunized with CR2(+) cell HABPs were determined by ELISA. B, shows the percentage of EBV-infected or noninfected cells that became fluorescent when anti-HABP-antibody recognition was determined by flow cytometry analysis. Fig. 4 . The effect of anti-HABP antibodies on EBV-binding to PBLs (CR2 (+) cells). PBLs were exposed to EBV in the presence (white bars) of anti-11382, -11389, -11416 antibodies or antibodies isolated from pre-immune sera (grey bars); then, IL-6 protein levels were determined by ELISA. Anti-HABP antibodies inhibited EBV-induced IL-6 protein in a similar way to how anti-EBV antibodies did (C(+)); on the contrary, anti non-relevant peptide antibodies (C(-)) did not have a detectable effect on IL-6 protein synthesis. Fig. 5 . PCR-amplification of EBV-DNA fragment using DNA obtained from CBLs treated with EBVcontaining supernatant. CBLs exposed to EBV, in the presence of HABPs or anti-HABP antibodies, were used for obtaining DNA for amplifying a specific fragment, using the previously reported EBV-primers. This fragment was separated on agarose gels. MWM = molecular weight markers is shown by the left arrow; C (+) and C (-) = EBV-PCR amplification using DNA obtained from non EBV-exposed and EBVexposed CBLs, respectively (see Materials and Methods). EBV-PCR amplification using DNA obtained from EBV-exposed to CBLs in the presence of HABPs (PEPTIDE), antibodies isolated from pre-immune sera or anti-HABP antibodies are shown. R1 and R2 represent the immunized rabbit number. The number of the peptide used in rabbit immunization appears at the right-hand side. Fig. 6 . CR2-C3dg chimerical complex structure. CR2-C3dg chimerical complex was constructed based on the resolved co-crystal structure of the C3dg-CR2 complex structure (Protein data bank code 1GHQ), in which C3dg-regions presenting homology with gp350 HABP-11382, 11389 and 11416 sequences were changed by these HABP-sequences. In yellow the ribbon structure of original the resolved co-crystal structure of the CR2-C3dg complex, except for C3dg-regions similar to HABP-11382 (in white), 11389 (in purple) and 11416 (in ice blue); in green CR2-C3dg chimerical complex, except for C3dg-regions changed by HABP-sequences (11382 in gray, 11389 in red and 11416 in blue). 
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